Prostate cancer
Prostate cancer Market

Prostate Cancer is a type of malignancy, occurs in the prostate gland that is a part of male reproductive system.


Prostate Cancer Epidemiological Segmentation 

The Epidemiological Segmentation of Prostate Cancer in 7MM from 2017 to 2030 is segmented as:- 

  • Total Prevalent Cases of Prostate Cancer
  • Total Diagnosed Cases of Prostate Cancer
  • Total Diagnosed Cases of Prostate Cancer patients by Clinical Stages
  • Prostate cancer cases by clinical stages –

         *Localized/ locally advanced cases (Stage I-III)

         *Biochemical recurrence/ progressive cases

         *Metastatic cases

  • Age Group-specific Cases of Prostate Cancer –

         *≤ 54 years;

         *55-64 years; 

         *65-74 years;

         *75-84 years;

         *>84 years

  • Prostate Cancer cases by Non-Metastatic CSPC/ CRPC and metastatic CSPC/ CRPC -

        *Non-metastatic castrate-sensitive prostate cancer (nmCSPC*/ nmHSPC*)

        *Non-metastatic castrate-resistant prostate cancer (nmCRPC*)

         *Metastatic castrate-sensitive prostate cancer (mCSPC/ mHSPC)

         *Metastatic castrate-resistant prostate cancer (mCRPC)

  • Total Treated Cases of mHSPC/CSPC and CRPC
  • Total Treated cases of Non-Metastatic CSPC/HSPC and CRPC  

* Hormone-Sensitive Prostate Cancer (HSPC)

* Castrate-Resistant Prostate Cancer (CRPC)

* Castrate-Sensitive Prostate Cancer (CSPC)


Prostate Cancer Epidemiology 

  • Total Prevalent cases of Prostate Cancer in 7MM in 2020 were7,494,882
  • Total Prevalent cases of Prostate Cancer in the United States in 2020 were 3,478,728


Prostate Cancer Market

The Market Size of Prostate Cancer is growing at 8.1% CAGR for the study period of 2017 to 2030.


Prostate Cancer Market Drivers

  • Increasing Use of Biomarker Testing
  • Rising Geriatric Population and High Prevalence Rate of Prostate Cancer
  • Surge in Awareness regarding the Treatment of Prostate Cancer
  • Increase in Demand for Prostate Cancer Treatment Products


Prostate Cancer Market Barriers

  • The complex issue of companion diagnostics
  • Cost Constraints 
  • Entry Barrier

 

Prostate Cancer Emerging Drugs

The emerging drugs of the Prostate Cancer market are 

  • Lynparza (Olaparib)
  • Opdivo (nivolumab)
  • 177Lu-PSMA-617
  • Relugolix
  • HC-1119
  • Seviteronel (VT-464)
  • PROSTVAC-V/F
  • ODM-208
  • Sacituzumab Govitecan (IMMU-132)
  • Keytruda (Pembrolizumab/MK-3475)
  • Ipatasertib (RG7440)
  • Talazoparib
  • Capivasertib (AZD5363): AZD4635
  • PRX302 (topsalysin): Pamiparib (BGB-290)
  • Enoblituzumab (MGA271)
  • Tisotumab Vedotin
  • Dupilumab
  • Rubraca (Rucaparib)
  • Niraparib
  • Proxalutamide (GT0918)
  • Abemaciclib (LY2835219)
  • Tomivosertib (eFT508)
  • Onvansertib
  • RV001V
  • ProstAtak

And many others.  


Prostate Cancer Key Players

The key players in the Prostate Cancer market are

  • AstraZeneca
  • Merck Sharp & Dohme
  • Bristol-Myers Squibb
  • Novartis
  • Myovant Sciences
  • Takeda
  • Hinova Pharmaceuticals
  • Innocrin Pharmaceutical
  • Bavarian Nordic
  • Orion Pharma
  • Immunomedics
  • Hoffmann-La Roche
  • Pfizer
  • Astellas Pharma
  • Sophiris Bio
  • BeiGene
  • MacroGenics
  • Genmab
  • Regeneron Pharmaceuticals
  • Clovis Oncology
  • Janssen Research & Development
  • Suzhou Kintor Pharmaceutical
  • Eli Lilly and Company
  • eFFECTOR Therapeutics
  • Trovagene
  • RhoVacz
  • Advantagene

And many others.